Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 46 entries
Sorted by: Best Match Show Resources per page
Therapy for chronic obstructive pulmonary disease in the 21st century.

Drugs

Donnelly LE, Rogers DF.
PMID: 12962514
Drugs. 2003;63(19):1973-98. doi: 10.2165/00003495-200363190-00002.

Chronic obstructive pulmonary disease (COPD) is a common, smoking-related, severe respiratory condition characterised by progressive, irreversible airflow limitation. Current treatment of COPD is symptomatic, with no drugs capable of halting the relentless progression of airflow obstruction. Better understanding of...

Cite
Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs. 2003;63(19):1973-98doi: 10.2165/00003495-200363190-00002.
Donnelly, L. E., & Rogers, D. F. (2003). Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs, 63(19), 1973-98. https://doi.org/10.2165/00003495-200363190-00002
Donnelly, Louise E, and Rogers, Duncan F. "Therapy for chronic obstructive pulmonary disease in the 21st century." Drugs vol. 63,19 (2003): 1973-98. doi: https://doi.org/10.2165/00003495-200363190-00002
Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs. 2003;63(19):1973-98. doi: 10.2165/00003495-200363190-00002. PMID: 12962514.
Copy Download .nbib Format: NLM
Treatment of obstructive airway diseases with roflumilast, a novel phosphodiesterase 4 inhibitor.

Expert review of clinical immunology

Bardin PG.
PMID: 20477153
Expert Rev Clin Immunol. 2007 Jul;3(4):469-76. doi: 10.1586/1744666X.3.4.469.

Obstructive airway diseases, chronic obstructive pulmonary disease (COPD) and asthma have a high prevalence worldwide and constitute a considerable burden of disease. Although various treatments have evolved for these illnesses, they are often only partially effective in relieving symptoms...

Cite
Bardin PG. Treatment of obstructive airway diseases with roflumilast, a novel phosphodiesterase 4 inhibitor. Expert Rev Clin Immunol. 2007;3(4):469-76doi: 10.1586/1744666X.3.4.469.
Bardin, P. G. (2007). Treatment of obstructive airway diseases with roflumilast, a novel phosphodiesterase 4 inhibitor. Expert review of clinical immunology, 3(4), 469-76. https://doi.org/10.1586/1744666X.3.4.469
Bardin, Philip G. "Treatment of obstructive airway diseases with roflumilast, a novel phosphodiesterase 4 inhibitor." Expert review of clinical immunology vol. 3,4 (2007): 469-76. doi: https://doi.org/10.1586/1744666X.3.4.469
Bardin PG. Treatment of obstructive airway diseases with roflumilast, a novel phosphodiesterase 4 inhibitor. Expert Rev Clin Immunol. 2007 Jul;3(4):469-76. doi: 10.1586/1744666X.3.4.469. PMID: 20477153.
Copy Download .nbib Format: NLM
Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases.

Drugs of today (Barcelona, Spain : 1998)

Crocker IC, Townley RG.
PMID: 12973397
Drugs Today (Barc). 1999 Jul;35(7):519-35. doi: 10.1358/dot.1999.35.7.548265.

Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease proliferation and cytokine secretion, whereas low concentrations have the opposite effect (1). Since many phosphodiesterases (PDEs) degrade cAMP, inhibitors of this...

Cite
Crocker IC, Townley RG. Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases. Drugs Today (Barc). 1999;35(7):519-35doi: 10.1358/dot.1999.35.7.548265.
Crocker, I. C., & Townley, R. G. (1999). Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases. Drugs of today (Barcelona, Spain : 1998), 35(7), 519-35. https://doi.org/10.1358/dot.1999.35.7.548265
Crocker, I C, and Townley, R G. "Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases." Drugs of today (Barcelona, Spain : 1998) vol. 35,7 (1999): 519-35. doi: https://doi.org/10.1358/dot.1999.35.7.548265
Crocker IC, Townley RG. Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases. Drugs Today (Barc). 1999 Jul;35(7):519-35. doi: 10.1358/dot.1999.35.7.548265. PMID: 12973397.
Copy Download .nbib Format: NLM
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.

RMD open

Gladman DD, Kavanaugh A, Gómez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ.
PMID: 30018799
RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018.

OBJECTIVE: The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial programme findings demonstrated that apremilast, an oral phosphodiesterase 4 inhibitor, is effective for treating psoriatic arthritis (PsA). Enthesitis and dactylitis are difficult-to-treat features of PsA leading to...

Cite
Gladman DD, Kavanaugh A, Gómez-Reino JJ, et al. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018;4(1):e000669doi: 10.1136/rmdopen-2018-000669.
Gladman, D. D., Kavanaugh, A., Gómez-Reino, J. J., Wollenhaupt, J., Cutolo, M., Schett, G., Lespessailles, E., Guerette, B., Delev, N., Teng, L., Edwards, C. J., Birbara, C. A., & Mease, P. J. (2018). Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD open, 4(1), e000669. https://doi.org/10.1136/rmdopen-2018-000669
Gladman, Dafna D, et al. "Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies." RMD open vol. 4,1 (2018): e000669. doi: https://doi.org/10.1136/rmdopen-2018-000669
Gladman DD, Kavanaugh A, Gómez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018. PMID: 30018799; PMCID: PMC6045740.
Copy Download .nbib Format: NLM
A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE).

Open forum infectious diseases

Boulougoura A, Gabriel E, Laidlaw E, Khetani V, Arakawa K, Higgins J, Rupert A, Gorelick RJ, Lumbard K, Pau A, Poole A, Kibiy A, Kumar P, Sereti I.
PMID: 31211164
Open Forum Infect Dis. 2019 Jun 03;6(6):ofz246. doi: 10.1093/ofid/ofz246. eCollection 2019 Jun.

OBJECTIVE: Phosphodiesterase 4 inhibitors (PDE4i) are novel anti-inflammatory medications that have been approved for rheumatologic diseases and have been tested as host-directed therapy in tuberculosis. We examined the safety of CC-11050, a potent PDE4i in people living with HIV...

Cite
Boulougoura A, Gabriel E, Laidlaw E, et al. A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE). Open Forum Infect Dis. 2019;6(6):ofz246doi: 10.1093/ofid/ofz246.
Boulougoura, A., Gabriel, E., Laidlaw, E., Khetani, V., Arakawa, K., Higgins, J., Rupert, A., Gorelick, R. J., Lumbard, K., Pau, A., Poole, A., Kibiy, A., Kumar, P., & Sereti, I. (2019). A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE). Open forum infectious diseases, 6(6), ofz246. https://doi.org/10.1093/ofid/ofz246
Boulougoura, Afroditi, et al. "A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)." Open forum infectious diseases vol. 6,6 (2019): ofz246. doi: https://doi.org/10.1093/ofid/ofz246
Boulougoura A, Gabriel E, Laidlaw E, Khetani V, Arakawa K, Higgins J, Rupert A, Gorelick RJ, Lumbard K, Pau A, Poole A, Kibiy A, Kumar P, Sereti I. A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE). Open Forum Infect Dis. 2019 Jun 03;6(6):ofz246. doi: 10.1093/ofid/ofz246. eCollection 2019 Jun. PMID: 31211164; PMCID: PMC6559277.
Copy Download .nbib Format: NLM
Update on the Pathogenesis and Therapy of Atopic Dermatitis.

Clinical reviews in allergy & immunology

Li H, Zhang Z, Zhang H, Guo Y, Yao Z.
PMID: 34338977
Clin Rev Allergy Immunol. 2021 Aug 02; doi: 10.1007/s12016-021-08880-3. Epub 2021 Aug 02.

Atopic dermatitis (AD) is a common inflammatory skin disorder characterized by recurrent eczematous lesions and intense itch. Although it most often starts in infancy and affects children, it is also highly prevalent in adults. In this article, the main...

Cite
Li H, Zhang Z, Zhang H, et al. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol. 2021;doi: 10.1007/s12016-021-08880-3.
Li, H., Zhang, Z., Zhang, H., Guo, Y., & Yao, Z. (2021). Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clinical reviews in allergy & immunology, . https://doi.org/10.1007/s12016-021-08880-3
Li, Huaguo, et al. "Update on the Pathogenesis and Therapy of Atopic Dermatitis." Clinical reviews in allergy & immunology vol. (2021). doi: https://doi.org/10.1007/s12016-021-08880-3
Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol. 2021 Aug 02; doi: 10.1007/s12016-021-08880-3. Epub 2021 Aug 02. PMID: 34338977.
Copy Download .nbib Format: NLM
Experimental Pharmacological Management of Psoriasis.

Journal of experimental pharmacology

Campione E, Cosio T, Di Prete M, Lanna C, Dattola A, Bianchi L.
PMID: 34345187
J Exp Pharmacol. 2021 Jul 26;13:725-737. doi: 10.2147/JEP.S265632. eCollection 2021.

Psoriasis is a chronic, relapsing, immune-mediated systemic disease. Its pathogenesis is complex and not fully understood yet. Genetic and epigenetic factors interact with molecular pathways involving TNF-α, IL-23/IL-17 axis, and peculiar cytokines, as IL-36 or phosphodiesterase 4. This review...

Cite
Campione E, Cosio T, Di Prete M, et al. Experimental Pharmacological Management of Psoriasis. J Exp Pharmacol. 2021;13:725-737doi: 10.2147/JEP.S265632.
Campione, E., Cosio, T., Di Prete, M., Lanna, C., Dattola, A., & Bianchi, L. (2021). Experimental Pharmacological Management of Psoriasis. Journal of experimental pharmacology, 13725-737. https://doi.org/10.2147/JEP.S265632
Campione, Elena, et al. "Experimental Pharmacological Management of Psoriasis." Journal of experimental pharmacology vol. 13 (2021): 725-737. doi: https://doi.org/10.2147/JEP.S265632
Campione E, Cosio T, Di Prete M, Lanna C, Dattola A, Bianchi L. Experimental Pharmacological Management of Psoriasis. J Exp Pharmacol. 2021 Jul 26;13:725-737. doi: 10.2147/JEP.S265632. eCollection 2021. PMID: 34345187; PMCID: PMC8323855.
Copy Download .nbib Format: NLM
Small Molecule Drugs in Inflammatory Bowel Diseases.

Pharmaceuticals (Basel, Switzerland)

Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M.
PMID: 34209234
Pharmaceuticals (Basel). 2021 Jun 30;14(7). doi: 10.3390/ph14070637.

Inflammatory bowel diseases (IBDs), mainly represented by Crohn's disease (CD) and Ulcerative Colitis (UC), are chronic disorders with an unclear pathogenesis. This incurable and iterative intestinal mucosal inflammation requires the life-long use of anti-inflammatory drugs to prevent flares or...

Cite
Ben Ghezala I, Charkaoui M, Michiels C, et al. Small Molecule Drugs in Inflammatory Bowel Diseases. Pharmaceuticals (Basel). 2021;14(7)doi: 10.3390/ph14070637.
Ben Ghezala, I., Charkaoui, M., Michiels, C., Bardou, M., & Luu, M. (2021). Small Molecule Drugs in Inflammatory Bowel Diseases. Pharmaceuticals (Basel, Switzerland), 14(7), . https://doi.org/10.3390/ph14070637
Ben Ghezala, Inès, et al. "Small Molecule Drugs in Inflammatory Bowel Diseases." Pharmaceuticals (Basel, Switzerland) vol. 14,7 (2021). doi: https://doi.org/10.3390/ph14070637
Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M. Small Molecule Drugs in Inflammatory Bowel Diseases. Pharmaceuticals (Basel). 2021 Jun 30;14(7). doi: 10.3390/ph14070637. PMID: 34209234; PMCID: PMC8308576.
Copy Download .nbib Format: NLM
The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review.

Chronic obstructive pulmonary diseases (Miami, Fla.)

Ohar JA, Donohue JF, Spangenthal S.
PMID: 31647856
Chronic Obstr Pulm Dis. 2019 Oct 23;6(4). doi: 10.15326/jcopdf.6.4.2019.0139.

UNLABELLED: Chronic obstructive pulmonary disease is the third leading cause of death and disease burden worldwide. It includes a spectrum of diseases including chronic bronchitis which is characterized by overproduction, hypersecretion and decreased elimination of mucus. Chronic bronchitis has...

Cite
Ohar JA, Donohue JF, Spangenthal S. The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review. Chronic Obstr Pulm Dis. 2019;6(4)doi: 10.15326/jcopdf.6.4.2019.0139.
Ohar, J. A., Donohue, J. F., & Spangenthal, S. (2019). The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review. Chronic obstructive pulmonary diseases (Miami, Fla.), 6(4), . https://doi.org/10.15326/jcopdf.6.4.2019.0139
Ohar, Jill A, et al. "The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review." Chronic obstructive pulmonary diseases (Miami, Fla.) vol. 6,4 (2019). doi: https://doi.org/10.15326/jcopdf.6.4.2019.0139
Ohar JA, Donohue JF, Spangenthal S. The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review. Chronic Obstr Pulm Dis. 2019 Oct 23;6(4). doi: 10.15326/jcopdf.6.4.2019.0139. PMID: 31647856; PMCID: PMC7006698.
Copy Download .nbib Format: NLM
Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety.

Journal of medicinal chemistry

Huang YY, Deng J, Tian YJ, Liang J, Xie X, Huang Y, Zhu J, Zhu Z, Zhou Q, He X, Luo HB.
PMID: 34520193
J Med Chem. 2021 Sep 23;64(18):13736-13751. doi: 10.1021/acs.jmedchem.1c01085. Epub 2021 Sep 14.

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease, and its incidence rate is rapidly rising. However, effective therapies for the treatment of IPF are still lacking. Phosphodiesterase 4 (PDE4) inhibitors were reported to be potential anti-fibrotic agents, but...

Cite
Huang YY, Deng J, Tian YJ, et al. Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety. J Med Chem. 2021;64(18):13736-13751doi: 10.1021/acs.jmedchem.1c01085.
Huang, Y. Y., Deng, J., Tian, Y. J., Liang, J., Xie, X., Huang, Y., Zhu, J., Zhu, Z., Zhou, Q., He, X., & Luo, H. B. (2021). Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety. Journal of medicinal chemistry, 64(18), 13736-13751. https://doi.org/10.1021/acs.jmedchem.1c01085
Huang, Yi-You, et al. "Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety." Journal of medicinal chemistry vol. 64,18 (2021): 13736-13751. doi: https://doi.org/10.1021/acs.jmedchem.1c01085
Huang YY, Deng J, Tian YJ, Liang J, Xie X, Huang Y, Zhu J, Zhu Z, Zhou Q, He X, Luo HB. Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety. J Med Chem. 2021 Sep 23;64(18):13736-13751. doi: 10.1021/acs.jmedchem.1c01085. Epub 2021 Sep 14. PMID: 34520193.
Copy Download .nbib Format: NLM
Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021).

Expert opinion on therapeutic patents

Liu Z, Liu M, Cao Z, Qiu P, Song G.
PMID: 34986723
Expert Opin Ther Pat. 2022 Jan 05; doi: 10.1080/13543776.2022.2026328. Epub 2022 Jan 05.

INTRODUCTION: Cyclic nucleotide phosphodiesterase 4 (PDE4) is responsible for the hydrolysis of cAMP, which has become an attractive therapeutic target for lung, skin, and severe neurological diseases. Nowadays, intensive efforts have been made to develop diverse PDE4 inhibitors for...

Cite
Liu Z, Liu M, Cao Z, et al. Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021). Expert Opin Ther Pat. 2022;doi: 10.1080/13543776.2022.2026328.
Liu, Z., Liu, M., Cao, Z., Qiu, P., & Song, G. (2022). Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021). Expert opinion on therapeutic patents, . https://doi.org/10.1080/13543776.2022.2026328
Liu, Zhihao, et al. "Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021)." Expert opinion on therapeutic patents vol. (2022). doi: https://doi.org/10.1080/13543776.2022.2026328
Liu Z, Liu M, Cao Z, Qiu P, Song G. Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021). Expert Opin Ther Pat. 2022 Jan 05; doi: 10.1080/13543776.2022.2026328. Epub 2022 Jan 05. PMID: 34986723.
Copy Download .nbib Format: NLM
Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021).

Expert opinion on therapeutic patents

Liu Z, Liu M, Cao Z, Qiu P, Song G.
PMID: 34986723
Expert Opin Ther Pat. 2022 Jan 17;1-18. doi: 10.1080/13543776.2022.2026328. Epub 2022 Jan 17.

INTRODUCTION: Cyclic nucleotide phosphodiesterase 4 (PDE4) is responsible for the hydrolysis of cAMP, which has become an attractive therapeutic target for lung, skin, and severe neurological diseases. Here, we review the current status of development of PDE4 inhibitors since...

Cite
Liu Z, Liu M, Cao Z, et al. Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021). Expert Opin Ther Pat. 2022;1-18doi: 10.1080/13543776.2022.2026328.
Liu, Z., Liu, M., Cao, Z., Qiu, P., & Song, G. (2022). Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021). Expert opinion on therapeutic patents, 1-18. https://doi.org/10.1080/13543776.2022.2026328
Liu, Zhihao, et al. "Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021)." Expert opinion on therapeutic patents vol. (2022): 1-18. doi: https://doi.org/10.1080/13543776.2022.2026328
Liu Z, Liu M, Cao Z, Qiu P, Song G. Phosphodiesterase‑4 inhibitors: a review of current developments (2013-2021). Expert Opin Ther Pat. 2022 Jan 17;1-18. doi: 10.1080/13543776.2022.2026328. Epub 2022 Jan 17. PMID: 34986723.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 46 entries